YU100303A - Pedijatrijski oblik gatifloksacina - Google Patents
Pedijatrijski oblik gatifloksacinaInfo
- Publication number
- YU100303A YU100303A YU100303A YUP100303A YU100303A YU 100303 A YU100303 A YU 100303A YU 100303 A YU100303 A YU 100303A YU P100303 A YUP100303 A YU P100303A YU 100303 A YU100303 A YU 100303A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- gatifloxacin
- taste
- found
- masked
- crystalline
- Prior art date
Links
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 title abstract 6
- 229960003923 gatifloxacin Drugs 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 2
- 239000002244 precipitate Substances 0.000 abstract 2
- 235000021314 Palmitic acid Nutrition 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 235000019658 bitter taste Nutrition 0.000 abstract 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940072132 quinolone antibacterials Drugs 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Seasonings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
U skladu sa sadašnjim pronalaskom obezbeđeno je tako hinolonsko antibakterijsko sredstvo, gatifloksacin pogodno maskiranog ukusa, koje se može koristiti u pedijatrijskim formulacijama. Za kristalni koprecipitat, gatifloksacina i jedne ili obe stearinske kiseline i palmitinske kiseline u uskom opsegu težinskih odnosa, nađeno je da efikasno maskira gorki ukus gatifloksacina. Ukus gatifloksacina se efikasno maskira u ustima i vodenoj suspenziji tokom celokupnog ciklusa doziranja, tipično četmaest dana.Nađeno je da se gatifloksacin iz navedenih kristalnih koprecipitata lako apsorbuje u stomaku.[There is provided in accordance with the present invention the quinolone antibacterial gatifloxacin adequately taste-masked so that it can be utilized for pediatric formulations. A crystalline co-precipitate of gatifloxacin and one or both of stearic acid and palmitic acid in a narrow weight ratio has been found to effectively mask the bitter taste of gatifloxacin. The taste of gatifloxacin is effectively masked in the mouth and in aqueous suspension through a full dosage cycle, typically fourteen days. Gatifloxacin in the subject crystalline co-precipitates has been found to be readily available for absorption from the stomach.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29962501P | 2001-06-20 | 2001-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU100303A true YU100303A (sh) | 2006-08-17 |
Family
ID=23155586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU100303A YU100303A (sh) | 2001-06-20 | 2002-05-10 | Pedijatrijski oblik gatifloksacina |
Country Status (29)
Country | Link |
---|---|
US (1) | US6589955B2 (sh) |
EP (1) | EP1406572A4 (sh) |
JP (1) | JP4617475B2 (sh) |
KR (1) | KR100888519B1 (sh) |
CN (1) | CN1264514C (sh) |
AR (1) | AR034483A1 (sh) |
AU (1) | AU2002345534B2 (sh) |
BG (1) | BG108444A (sh) |
BR (1) | BR0209692A (sh) |
CA (1) | CA2450742A1 (sh) |
CZ (1) | CZ20033487A3 (sh) |
EE (1) | EE200400018A (sh) |
GE (1) | GEP20053610B (sh) |
HR (1) | HRP20031027A2 (sh) |
HU (1) | HUP0401497A2 (sh) |
IL (1) | IL158863A0 (sh) |
IS (1) | IS7048A (sh) |
MX (1) | MXPA03011451A (sh) |
NO (1) | NO20035605D0 (sh) |
NZ (1) | NZ529611A (sh) |
PE (1) | PE20030126A1 (sh) |
PL (1) | PL366559A1 (sh) |
RU (1) | RU2288218C2 (sh) |
SK (1) | SK14152003A3 (sh) |
TW (1) | TWI224004B (sh) |
UA (1) | UA75656C2 (sh) |
WO (1) | WO2003000175A2 (sh) |
YU (1) | YU100303A (sh) |
ZA (1) | ZA200309173B (sh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2258349B1 (en) | 2004-05-11 | 2014-07-16 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US8524734B2 (en) * | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US20070051418A1 (en) * | 2005-09-02 | 2007-03-08 | Rowles Brian A | Multilayer tubes |
TW201010708A (en) * | 2008-06-02 | 2010-03-16 | Intervet Int Bv | Composition comprising an antibiotic and a corticosteroid |
LT2344129T (lt) | 2008-10-07 | 2018-05-10 | Horizon Orphan Llc | Aerozolinės fluorchinolono kompozicijos, skirtos farmakokinetikų pagerinimui |
ES2809177T3 (es) | 2008-10-07 | 2021-03-03 | Horizon Orphan Llc | Inhalación de levofloxacino para reducir la inflamación pulmonar |
RU2563809C2 (ru) | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
CN102397552B (zh) * | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
BR112015023044A8 (pt) | 2013-03-15 | 2021-09-28 | Melinta Subsidiary Corp | Métodos para tratar infecções em pacientes acima do peso e obesos com o uso de antibióticos |
US20180118747A1 (en) * | 2017-01-03 | 2018-05-03 | Thermolife International, Llc | Method of isolating theacrine and composition comprising theacrine |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO88836A2 (ro) | 1983-10-11 | 1986-03-31 | Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro | Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric |
JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
NL193682C (nl) | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
US5405617A (en) | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
IT1255792B (it) | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
US5407921A (en) | 1993-07-01 | 1995-04-18 | Kao Corporation | Method for suppressing bitter taste |
JP3449658B2 (ja) | 1994-12-21 | 2003-09-22 | 杏林製薬株式会社 | 安定性に優れた8−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
DE19633480A1 (de) | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
CA2227314A1 (en) | 1997-01-24 | 1998-07-24 | Hoechst Aktiengesellschaft | Preparation of concealed taste preparations of antibacterially active quinolone derivatives |
GB9702799D0 (en) | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
ATE411047T1 (de) | 1999-07-14 | 2008-10-15 | Schering Plough Ltd | Maskieren des geschmacks der oralen flüssigen chinolon-zubereitungen mit ionenaustauscherharzen |
-
2002
- 2002-05-09 US US10/143,487 patent/US6589955B2/en not_active Expired - Lifetime
- 2002-05-10 YU YU100303A patent/YU100303A/sh unknown
- 2002-05-10 EE EEP200400018A patent/EE200400018A/xx unknown
- 2002-05-10 MX MXPA03011451A patent/MXPA03011451A/es active IP Right Grant
- 2002-05-10 AU AU2002345534A patent/AU2002345534B2/en not_active Ceased
- 2002-05-10 SK SK1415-2003A patent/SK14152003A3/sk unknown
- 2002-05-10 NZ NZ529611A patent/NZ529611A/en unknown
- 2002-05-10 CZ CZ20033487A patent/CZ20033487A3/cs unknown
- 2002-05-10 EP EP02744141A patent/EP1406572A4/en not_active Withdrawn
- 2002-05-10 CA CA002450742A patent/CA2450742A1/en not_active Abandoned
- 2002-05-10 BR BR0209692-7A patent/BR0209692A/pt not_active IP Right Cessation
- 2002-05-10 IL IL15886302A patent/IL158863A0/xx unknown
- 2002-05-10 HU HU0401497A patent/HUP0401497A2/hu unknown
- 2002-05-10 KR KR1020037016647A patent/KR100888519B1/ko not_active IP Right Cessation
- 2002-05-10 CN CNB02812409XA patent/CN1264514C/zh not_active Expired - Fee Related
- 2002-05-10 RU RU2003136068/04A patent/RU2288218C2/ru not_active IP Right Cessation
- 2002-05-10 JP JP2003506621A patent/JP4617475B2/ja not_active Expired - Fee Related
- 2002-05-10 WO PCT/US2002/014596 patent/WO2003000175A2/en not_active Application Discontinuation
- 2002-05-10 GE GE5383A patent/GEP20053610B/en unknown
- 2002-05-10 PL PL02366559A patent/PL366559A1/xx not_active Application Discontinuation
- 2002-06-13 AR ARP020102227A patent/AR034483A1/es not_active Application Discontinuation
- 2002-06-14 TW TW091113074A patent/TWI224004B/zh not_active IP Right Cessation
- 2002-06-18 PE PE2002000518A patent/PE20030126A1/es not_active Application Discontinuation
- 2002-10-05 UA UA20031211971A patent/UA75656C2/uk unknown
-
2003
- 2003-11-20 IS IS7048A patent/IS7048A/is unknown
- 2003-11-25 ZA ZA200309173A patent/ZA200309173B/en unknown
- 2003-12-10 HR HR20031027A patent/HRP20031027A2/hr not_active Application Discontinuation
- 2003-12-12 BG BG108444A patent/BG108444A/xx unknown
- 2003-12-16 NO NO20035605A patent/NO20035605D0/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108444A (en) | Pediatric formulation of gatifloxacin | |
CA2478411C (en) | Palatable oral suspension and method | |
ATE517624T1 (de) | Behandlung von neurodegenerativen erkrankungen und krebs im gehirn | |
IL164108A (en) | Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders | |
EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
HUP0000450A2 (hu) | 7-(2-Oxa-5,8-diazabiciklo[4.3.0]non-8-il)-kinolon-karbonsav és -naftiridon-karbonsav-származékok alkalmazása Helicobacter pylori fertőzések, és az ezzel kapcsolatos gyomor-bél megbetegedések gyógyítására szolgáló gyógyszerkészítmények előállítására | |
ATE361077T1 (de) | Indanylderivate zur behandlung von atemwegserkrankungen | |
IL167250A (en) | Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases | |
HK1045464A1 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease | |
MXPA05010161A (es) | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. | |
EP2047854A1 (en) | Pharmaceutical formulations containing ferrous bisglycinate chelate in combination with sweeteners (acesulfam K, sucralose, sorbitol) for improved palatability | |
UY27339A1 (es) | Formulación pediátrica de gatifloxacina | |
PL353992A1 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
NO20014061D0 (no) | Krystallmodifikasjon C av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-(4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre | |
DE60004846D1 (de) | Quinolincarbonsäure-derivate oder salze davon | |
JP2003342186A (ja) | 鼻炎用内服液剤組成物 | |
AU2003255111A8 (en) | The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
WO2004082589A3 (en) | Nasally administrable, bioavailable pharmaceutical composition of loratadine | |
CN103977081A (zh) | 一种口咽抑菌和提高口咽免疫力的组合物及其制备和用途 | |
JOP20180124A1 (ar) | لقاح لفيروس الروتا ذو حجم جرعة منخفض مستقر حمضياً وخالى من المحلول المنظم | |
TH19997A (th) | ผลึกของสารประกอบต่อต้านการเจริญของจุลินทรีย์ |